鉴定VDAC1作为Ginkgolide B的心脏保护性标
Tingbiao Wu1, Deyao Li2, Qiuyu Chen1
1School of Bioengineering, Zhuhai Campus of Zunyi Medical University, Zhuhai, 519000, China.
Chemico-biological interactions
|December 24, 2024
概括
银高化物B (GB) 通过向电压依赖性离子通道1 (VDAC1) 来保护心脏. 这种相互作用改善了线粒体功能并减少了细胞死亡,为心脏保护提供了新的策略.
科学领域:
- 心血管研究研究心血管研究
- 线粒体生物学 线粒体生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 银杏花B (GB) 是银杏花的天然化合物,具有心脏保护作用.
- GB 保护心脏的特定分子标和机制尚不清楚.
研究的目的:
- 使用一种新型的探测器识别戈利德B (GB) 的分子标.
- 阐明确定目标在GB介导心脏保护中的作用.
主要方法:
- 用生物素标记的GB探针 (GB-生物素) 合成用于目标识别.
- 评估线粒体功能 (膜潜力,氧气消耗) 和亡.
- 蛋白质组分析,细胞热转移试验 (CETSA) 和分子对接以确认目标相互作用.
- 基因操纵 (VDAC1过度表达) 来验证目标功能.
主要成果:
- GB和GB-生物素治疗减少了线粒体损伤和亡,增强了线粒体功能.
- 蛋白质组分析确定了电压依赖性离子通道1 (VDAC1) 作为一种与GB相互作用的蛋白质.
- CETSA和分子对接证实了GB和VDAC1.1之间的直接结合.
- 过度表达VDAC1消除了GB的心脏保护作用.
结论:
- 电压依赖性阳离子通道1 (VDAC1) 被确定为金克戈利德B (GB) 的关键分子标.
- 通过与VDAC1相互作用,GB发挥心脏保护作用,改善线粒体生物能学和减少亡.
- VDAC1代表了开发涉及GB的新型心脏保护策略的潜在治疗标.
更多相关视频
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
1.8K
05:58Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
116
相关概念视频
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
